4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboximidic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 四环素类
• 英文名称: 4-(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboximidic acid
• 英文别名: 6-Desoxy-6-demethyl-tetracyclin；6-Demethyl-6-deoxy-tetracyclin；6-Desmethyl-6-desoxy-tetracyclin
• 化学式: C21H22N2O7
• InChiKey: XDVCLKFLRAWGIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.12
• 重原子数：
  30.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  161.39
• 氢给体数：
  5.0
• 氢受体数：
  8.0

文献信息

• Substituted Tetracycline Compounds
  申请人：Kim Oak K.

  公开号：US20100305072A1

  公开（公告）日：2010-12-02

  The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

  本发明至少部分涉及新型替代四环素化合物。这些四环素化合物可用于治疗许多对四环素化合物敏感的疾病状态，如细菌感染和肿瘤。
• TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20180016225A1

  公开（公告）日：2018-01-18

  Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

  使用具有目标治疗活性的四环素化合物治疗疾病的方法和化合物被描述。
• METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20150321997A1

  公开（公告）日：2015-11-12

  A method for modulating RNA with tetracycline compounds is described.

  描述了一种用四环素化合物调节RNA的方法。
• Compounds and methods for the treatment of pain and other diseases
  申请人：Sucholeiki Irving

  公开号：US20110230452A1

  公开（公告）日：2011-09-22

  The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.

  本发明通常涉及制药剂，特别是金属蛋白酶抑制剂化合物。更具体地，本发明提供了一类新的双重作用MMP-2和MMP-9抑制化合物，这些化合物在与目前已知的MMP-2和MMP-9抑制剂相比具有增强的效力、代谢稳定性和/或降低的毒性，用于治疗疼痛和其他疾病。此外，本发明涉及一种治疗疼痛、成瘾和/或戒断症状的方法，包括向患者施用一定量的具有减轻疼痛作用的本发明化合物。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE LA DOULEUR ET D'AUTRES TROUBLES
  申请人：SUCHOLEIKI IRVING

  公开号：WO2012118498A1

  公开（公告）日：2012-09-07

  The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.

  本发明一般涉及制药剂，特别是金属蛋白酶抑制剂化合物。更具体地说，本发明提供了一类新的双重作用MMP-2和MMP-9抑制化合物，其在与目前已知的MMP-2和MMP-9抑制剂相比，表现出增强的效力、代谢稳定性和/或降低的毒性，用于治疗疼痛和其他疾病。此外，本发明涉及一种治疗疼痛、成瘾和/或戒断症状的方法，包括向患者投予一种疼痛减轻有效量的当前化合物。